Feb 22, 2021
On today's episode of InsideOut, I'm joined by guest Diana Brainard, SVP and Virology Therapeutic Area Head at Gilead, to talk about the challenges and triumphs of launching a new therapy during the COVID-19 pandemic.
We dive into Remdesivir, an antiviral originally designed to target Ebola and later tested against a suite of lesser-known respiratory viruses. We discuss how Gilead moved the therapy into the clinic as quickly as possible to fight the COVID-19 pandemic. The outcome? It was one of only a few therapies granted emergency use authorization to treat severe COVID-19 patients in the pandemic’s earliest days.